Table of contents
- Clinical trials overview
- Trials in atopic dermatitis and eczema
- Trial in dry foot skin with diabetes
- What the trials measure
- Who the trials are for
- Trial phases and status
Clinical trials overview
The clinical trial data for Urea focuses on moisturiser studies in skin disease, not on general drug use.[1][2][3][4] The main conditions studied are atopic dermatitis, also called eczema, and xerotic skin on the feet in people with diabetes.[1][3] These are interventional studies, which means researchers give a treatment and compare results across groups.[1][2]
Trials in atopic dermatitis and eczema
Two trials studied moisturiser treatment for atopic dermatitis, one in children and one in adults.[1][2] The child study was a Phase 3 trial with 270 participants and aimed to show that a newly developed moisturiser could better prevent eczema relapse than a reference cream.[1] In this study, relapse meant a return of eczema that the child, parent, or legal guardian felt needed stronger treatment, and the date of relapse was recorded in an eDiary and confirmed by the investigator.[1]
The adult study was a Phase 2 trial with 55 participants and tested whether a new moisturiser, Propyduo®, could strengthen the skin barrier better than no treatment and better than Propyless® over 4 weeks.[2] The brief summary says the study included adults with a history of atopic dermatitis.[2] This trial helps show whether a moisturiser can improve skin barrier function in people who have had eczema before.[2]
A later authorised Phase 2 trial is also studying maintenance treatment for atopic dermatitis in 78 participants.[4] It compares Oviderm cream with a Urea/propylene glycol cream and looks at time to relapse of eczema during the maintenance phase.[4] The outcome is patient-reported, meaning the person in the study reports when the eczema comes back.[4]
Trial in dry foot skin with diabetes
One authorised Phase 3 trial studies creams for dry foot skin in people with diabetes.[3] The condition is described as xerotic skin on the foot of subjects with diabetes, and the study compares Oviderm with Canoderm 5% cream.[3] The goal is to show that the test product is better than the comparator in reducing xerosis, which means very dry skin, after 4 weeks of treatment.[3]
What the trials measure
The main outcome in the child eczema trial is relapse of atopic eczema, measured as a hazard ratio.[1] A hazard ratio compares how often an event happens in one group versus another over time.[1] In the adult skin-barrier trial, the main measure is Trans Epidermal Water Loss (TEWL), which shows how much water escapes through the skin.[2] Lower water loss usually suggests a stronger skin barrier, so this test helps researchers compare the creams.[2]
The diabetes foot study uses the Xerosis Severity Scale to judge how dry the skin is before and after treatment.[3] The maintenance eczema study measures time to relapse of eczema from baseline until relapse or the end of the maintenance phase, whichever comes first.[4] These endpoints show whether the creams help people stay stable for longer or improve dryness and barrier function.[1][2][3][4]
Who the trials are for
The target groups differ by trial, but all are focused on skin problems where moisturising treatment may help.[1][2][3][4] One study is for children with atopic dermatitis, another for adults with a history of atopic dermatitis, and another for people with diabetes who have dry feet.[1][2][3] The authorised maintenance trial also includes people with atopic dermatitis.[4]
Children with eczema: The goal is to see if a moisturiser can keep eczema from coming back.[1]
Adults with past eczema: The goal is to see if a moisturiser improves the skin barrier after 4 weeks.[2]
People with diabetes and dry feet: The goal is to see if a cream can reduce very dry skin on the feet.[3]
People in maintenance treatment: The goal is to see how long eczema stays away during ongoing care.[4]
Trial phases and status
The trial data includes Phase 2 and Phase 3 studies.[1][2][3][4] Phase 2 studies are usually smaller and look for early signs that a treatment may work, while Phase 3 studies are larger and compare treatments more directly.[1][2][3][4] Two studies are completed, and two are authorised.[1][2][3][4]
The completed studies include the Phase 3 child eczema relapse trial and the Phase 2 adult skin-barrier trial.[1][2] The authorised studies include the Phase 3 diabetes foot dryness trial and the Phase 2 maintenance eczema trial.[3][4] Enrollment ranged from 55 to 270 in the studies with reported numbers, showing that the trials vary in size depending on the research question.[1][2][4]





